Company: CRNX
Filing Date: 2025-04-04
Form Type: 8-K
Source: 0000950170-25-051179
Chunk: 1

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-04
Form: 8-K
Item: Item 5.02
Chunk 1
---
 of the Company. In addition, upon a Change in Control (as defined in the Plans), any outstanding but unvested equity awards held by Mr. Wilson that would otherwise vest through the end of the applicable Consulting Period will automatically vest if such awards are not assumed, substituted or continued by the acquiror and Mr. Wilson continues to provide Services following such Change in Control. Further, any vested and outstanding stock options held by Mr. Wilson as of the end of the Consulting Period will remain exercisable for three years following such date, or the original term of such stock options, if earlier, provided that all outstanding stock options shall be immediately forfeited upon Mr. Wilson’s termination for Cause. On the terms set forth in the Consulting Agreement, Mr. Wilson also agreed to a general release of all claims in favor of the Company with respect to Mr. Wilson’s departure from the Company, including under that certain Amended and Restated Employment Agreement, dated May 22, 2018, between Mr. Wilson and the Company, and the Company agreed to extend certain indemnification rights to Mr. Wilson during the term of the Consulting Agreement.

The foregoing description of the Consulting Agreement is not complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.